Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;6(2):83-91.
doi: 10.1007/s40801-019-0154-4.

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab

Marina Magrey  1 , Michael Bozyczko  2 , Daniel Wolin  3 , Margaret Mordin  3 , Lori McLeod  3 , Eric Davenport  3 , Costel Chirila  3 , Yujin Park  4
Affiliations

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab

Marina Magrey et al. Drugs Real World Outcomes. 2019 Jun.

Abstract

Purpose: This real-world study evaluated the feasibility of assessing patient-reported symptom improvement and treatment satisfaction using a web-based survey among patients with ankylosing spondylitis (AS) treated with secukinumab.

Methods: This cross-sectional, web-based survey collected data on demographics, symptoms, treatment history, and treatment satisfaction from US patients with AS who were receiving secukinumab at survey participation. Patients reported AS symptoms experienced before and after secukinumab initiation, time to symptom improvement, and satisfaction with secukinumab treatment.

Results: Of 2755 patients screened, 200 with AS were included in the analysis. The mean (SD) age of patients was 34.4 (10.6) years; 86.5% were biologic experienced. Most (74.0%) reported overall improvement ("a little," "moderately," or "much better") in AS symptoms since secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all the individual symptoms analyzed (pain disrupting sleep, fatigue, morning stiffness, pain and stiffness in lower back or neck, sore areas other than joints, and ankle or heel pain [indicating enthesitis]). Approximately 41.9% of patients reported overall symptom improvement within 4 weeks of secukinumab treatment. Most expressed overall satisfaction ("very," "mostly," or "somewhat satisfied") with secukinumab regarding symptom improvement (99.0%), speed of symptom improvement (97.0%), frequency and method of administration (96.0% and 91.5%, respectively), ease of use (93.5%), patient support services (97.0%), and side effects, if any (93.0%).

Conclusion: Most patients reported overall symptom improvement and satisfaction with treatment. Our study indicates that patient-reported perspectives may be feasibly collected using a web-based survey to provide insights into treatment experience and satisfaction.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

M. Magrey served as a consultant for Novartis. M. Bozyczko has nothing to disclose. D. Wolin, M. Mordin, L. McLeod, E. Davenport, and C. Chirila are employees of RTI Health Solutions. Y. Park is an employee of Novartis.

Research involving human participants

An institutional review board exemption was obtained for the study prior to initiation of data collection.

Informed consent

Informed consent was obtained electronically from eligible patients interested in participating in this AS survey.

Figures

Fig. 1
Fig. 1
Proportion of patients experiencing AS symptoms before and after initiating secukinumab in a the overall population (N = 200), b patients with 3–6 months of secukinumab use (n = 72), c patients with 7–12 months of secukinumab use (n = 71), and d patients with > 12 months of secukinumab use (n = 57). AS ankylosing spondylitis
Fig. 2
Fig. 2
Patient-reported time to first noticeable improvement in AS symptoms since secukinumab initiation. AS ankylosing spondylitis
Fig. 3
Fig. 3
Overall treatment satisfaction with secukinumab for AS (n = 193). AS ankylosing spondylitis
See this image and copyright information in PMC

References

    1. Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650–657. - PubMed
    1. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–2137. - PubMed
    1. Jang JH, Ward MM, Rucker AN, et al. Ankylosing spondylitis: patterns of radiographic involvement: a re-examination of accepted principles in a cohort of 769 patients. Radiology. 2011;258:192–198. - PMC - PubMed
    1. Oldroyd J, Schachna L, Buchbinder R, et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol. 2009;2009:268569. - PMC - PubMed
    1. Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis. 2010;69:1165–1168. - PubMed